At baseline, Tim-3 expression levels were significantly higher in patients with AML and high-risk MDS compared to lower-risk MDS (mean fold-change increase ± SD, 0.94 ± 0.6 vs. 0.4 ± 0.3, AML and high-risk vs. lower-risk MDS; p = 0.0303) (Figure 3D); however, no significant differences were described during treatment and regardless responsiveness to therapy (all p > 0.05). The gene discussed is HAVCR2; the disease is myelodysplastic syndrome.